Trial Profile
To compare patient persistence of fingolimod with other disease modifying therapies in patients with relapsing remitting multiple sclerosis in Australia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Nov 2017
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 28 Oct 2017 Results presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
- 21 Oct 2017 New trial record
- 12 Oct 2017 Results (n=720) presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research